Aenova Invests Further in Kerry with Advanced Pharmaceutical Capabilities
Aenova, a leading pharmaceutical Contract Development & Manufacturing Organisation (CDMO), has announced a significant expansion of its Killorglin facility, Temmler Ireland Ltd., marking a welcome boost for enterprise and local employment in County Kerry. This strategic investment will enhance the site’s development capabilities and position the Kerry facility at the heart of Aenova’s global innovation in drug delivery systems.
The Killorglin site will become a centre of excellence for particle engineering within the Aenova Group, specialising in advanced technologies such as spray-dried amorphous solid dispersions and inhalation powders. These developments aim to improve the bioavailability of poorly soluble drugs — a critical focus in pharmaceutical research, as such compounds represent approximately 80% of the global development pipeline.
The project is supported by the Irish Government through IDA Ireland, reflecting continued commitment to regional development and innovation.
Government Welcomes High-Value Jobs and Regional Investment
Speaking about the announcement, Minister for Enterprise, Trade and Employment, Peter Burke TD, stated:
“I warmly congratulate Aenova on this exciting expansion of its Killorglin facility, which not only strengthens Ireland’s position in advanced pharmaceutical development but also brings high-value employment to County Kerry. This investment is a strong vote of confidence in the South-West region’s skilled workforce, world-class research partnerships, and thriving life sciences ecosystem.”
“The Government, through IDA Ireland, is proud to support Aenova’s growth, and this announcement is a further step in delivering on our ambition for balanced, sustainable economic growth across all parts of Ireland. I wish the Aenova team the very best for the future.”
Minister for Children, Disability and Equality, Norma Foley TD added:
“I welcome Aenova’s substantial investment in their pharmaceutical facility in Killorglin, which has led to the creation of 10 new jobs in research and development, pharmaceutical technology and analytics. This is a resounding endorsement of the talented workforce here and shows what an attractive location Kerry is for inward investment. I wish to congratulate Aenova and I look forward to working with the company into the future.”
Killorglin Site Builds on Strong Legacy in Pharma Innovation
Founded in 1972 as Klinge Pharma, the Killorglin site has a long-standing presence in Kerry’s business landscape. It currently employs around 70 people directly, with many more supported through downstream service providers. The facility was acquired by Temmler Pharma in 2007, and in 2012 became part of the Aenova Group — one of Europe’s leading CDMO companies in the pharmaceutical and nutraceutical sectors.
Florent Bordet, Chief Scientific Officer at Aenova commented:
“As an end-to-end CDMO, Aenova supports its customers throughout the entire drug product lifecycle, from pre-formulation and development to commercial manufacturing. Bioavailability is crucial for new pharmaceutical active ingredients. Our new spray drying technology in Killorglin can help to address this issue and aid our customers bring their products to market faster,”
New Roles and Academic Collaboration Drive Innovation in Kerry
The expansion will see the creation of 10 highly skilled roles in the areas of R&D, Pharmaceutical Technology, and Analytics — reinforcing the importance of local talent and innovation in Kerry’s growing life sciences sector. Aenova’s continued investment in Killorglin demonstrates the region’s strength as a base for high-value international business and pharmaceutical innovation. To explore opportunities to join the team in Killorglin, visit Aenova Careers.
Aidan Spillane, Managing Director at Aenova Killorglin, highlighted:
“Aenova’s spray drying services for amorphous solid dispersions are located at our Killorglin site. Here, we offer laboratory- and pilot-scale equipment for developing formulations, using APIs (Active Pharmaceutical Ingredients) up to OEB 4 (>1 µg/m³). We have the capability to handle organic solvents, and we collaborate closely with scientific researchers at the universities of Cork and Limerick."
